While the new mRNA vaccines from Moderna and Pfizer-BioNTech have dominated the COVID-19 vaccine story, there is another type ...

Novavax Inc. closed $11.06 below its 52-week high ($23.86), which the company achieved on June 6th.

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

The latest flu vaccines are now available, and just like the COVID-19 shots, it's recommended to get the flu shot in ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

For those who are uninsured or under-insured, CDPH will have vaccine at its three CDPH Immunization Clinics. Walk-ins are ...

The Novavax vaccine, which was approved by the FDA at the end of August, is the only non-mRNA updated COVID vaccine that is ...

With the approval of Moderna's updated COVID-19 vaccine, doctors are hoping the shots will be available soon and Albertans ...

Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the ...

The latest trading session saw Novavax (NVAX) ending at $12.80, denoting a -0.85% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily gain of 0.28%. Meanwhile ...

There's a new bulletin from Florida's surgeon general. Vaccine experts and historians interviewed for this article can’t ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...